Berberine ursodeoxycholate
Berberine ursodeoxycholate has been studied in 4 papers since 2020: 2 trials in people, 2 reviews; 1 in the past year. The newest paper, Sep 17, 2021: “A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes”.
“subjects receiving 1000 mg twice a day of berberine ursodeoxycholate had significantly greater reduction in liver fat content than in placebo recipients (mean absolute decrease -4.8% vs. -2.0% (p = 0.011)”
- 1 lab in 2 countries
- Funders: BioClinica and 2 more
- 7 of 7 findings with company ties
- Human trial2
What did studies of Berberine ursodeoxycholate find?
7Studies of Berberine ursodeoxycholate measured 7 outcomes; the most studied are liver-associated enzymes (1 study), body weight (1) and glycemic control (1).
Liver-associated enzymes
downin humans1
1 study
Liver-associated enzymes
downin humans1
Berberine ursodeoxycholate decreases liver-associated enzymes in humans.
“reductions in liver-associated enzymes”
Human trialpresumed non-alcoholic steatohepatitis and type 2 diabetesliver1000 mg twice a day18 weeks
Nature communications
Body weight
downin humans1
1 study
Body weight
downin humans1
Berberine ursodeoxycholate decreases body weight in humans.
“subjects receiving this dose also experienced significant improvement in glycemic control as well as reductions in liver-associated enzymes and significant weight loss.”
Human trialpresumed non-alcoholic steatohepatitis and type 2 diabetes1000 mg twice a day18 weeks
Nature communications
Glycemic control
upin humans1
1 study
Glycemic control
upin humans1
Berberine ursodeoxycholate improves glycemic control in humans.
“Compared to placebo, subjects receiving this dose also experienced significant improvement in glycemic control”
Human trialpresumed non-alcoholic steatohepatitis and type 2 diabetes1000 mg twice a day18 weeks
Nature communications
Liver fat content
downin humans1
1 study
Liver fat content
downin humans1
Berberine ursodeoxycholate decreases liver fat content in humans (-4.8% vs. -2.0% (p = 0.011)).
“subjects receiving 1000 mg twice a day of berberine ursodeoxycholate had significantly greater reduction in liver fat content than in placebo recipients (mean absolute decrease -4.8% vs. -2.0% (p = 0.011)”
Human trialpresumed non-alcoholic steatohepatitis and type 2 diabetesliver1000 mg twice a day18 weeks
Nature communications
Triglyceride
no changein humans1
1 study
Triglyceride
no changein humans1
Berberine ursodeoxycholate has no effect on triglyceride in humans.
“but no significant changes in triglyceride and HDL cholesterol concentrations”
Human trialin patients with hypercholesterolemia2000 mg per day28 days
Lipids in health and disease
Total cholesterol
downin humans1
1 study
Total cholesterol
downin humans1
Berberine ursodeoxycholate decreases total cholesterol in humans (-8.2% (P = 0.0004)).
“there were significant reductions in the serum concentrations of total cholesterol by 8.2% (P = 0.0004)”
Human trialin patients with hypercholesterolemia2000 mg per day28 days
Lipids in health and disease
LDL cholesterol
downin humans1
1 study
LDL cholesterol
downin humans1
Berberine ursodeoxycholate decreases LDL cholesterol in humans (-10.4% (P = 0.0006)).
“By day 28 and with the highest dose of BUDCA, there were significant reductions in the serum concentrations of total cholesterol by 8.2% (P = 0.0004) and LDL cholesterol by 10.4% (P = 0.0006)”
Human trialin patients with hypercholesterolemia2000 mg per day28 days
Lipids in health and disease